Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Cancer chemotherapy has been one of the major medical advances in the last few decades.
However, the drugs used for this therapy have a narrow therapeutic index, and often the …

Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of
the improvements in the life quality of patients, their effectiveness is compromised by several …

Abstract Background Receptor tyrosine kinases (RTKs) are signaling enzymes responsible
for the transfer of Adenosine triphosphate (ATP) γ-phosphate to the tyrosine residues …

Molecular targeted therapies with tyrosine kinase inhibitors (TKIs) have been a recent
breakthrough in cancer treatment. These small molecules are mainly used at a fixed dose …

Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …

Background The epidermal growth factor receptor (EGFR) pathway is important in tumor
growth, survival, and metastasis and is now the target of several therapeutic agents …

Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential
role in the molecular pathways, leading to cell survival and differentiation. Consequently …

Targeted protein-tyrosine kinase inhibitors (PTKIs) comprise a new, rapidly evolving class of
low molecular weight anticancer drugs. Two members of this class, imatinib (Gleevec) and …

Small molecule tyrosine kinase inhibitors (TKIs) are developed to block intracellular
signaling pathways in tumor cells, leading to deregulation of key cell functions such as …